No abstract

No abstract

No abstract

Non-alcoholic steatohepatitis (NASH), defined as excess hepatic lipid and chronic inflammation, provides an environment prone for the development of hepatic fibrosis. Recent evidence suggests that the antifibrotic protein BAMBI (BMP-Activin membrane bound inhibitor) is downregulated in the presence of inflammation, and may be central to the development of fibrosis. Diets rich in omega-3 (-3) fatty acids are known to provide anti-inflammatory effects; however, the effects of -3 fatty acids on hepatic fibrosis are not well-established. PURPOSE: To determine the effects of fish-oils on the hepatic fibrosis signaling cascade, following 32-weeks of high-fat feeding in a LPS-induced model of NASH. METHODS: Male C57BL/6 mice were randomly assigned to one of four diets for 32 weeks (n=9/group): low-fat lard based (LFL, 10% kcal fat), low-fat fish-oil based (LFFO, 10% kcal fat), high-fat lard based (HFL, 41% kcal fat), or high-fat fish-oil based (HFFO, 41% kcal fat). Following in situ LPS stimulation, liver mRNA expression of CD14, TLR4, MyD88, BAMBI, and TGF-β1 was quantified using quantitative RT-PCR. Differences between diets were identified using a one-way ANOVA with statistical significance set at p<0.05. RESULTS: Following LPS stimulation, CD14 was increased 2.5 fold (p=0.020) in HFFO when compared to HFL. Despite the increase in CD14, TLR4 showed no difference between groups. In contrast, MyD88 was 2.8 fold greater (p<0.001) in HFL compared to HFFO. In comparison to untreated tissue, BAMBI was 1.7 fold (p=0.017) higher in the HFFO LPS-stimulated tissue, which best explained the 1-fold (p=0.004) lower expression of TGF-β1 in HFFO when compared to HFL post-LPS stimulation. CONCLUSION: Despite the increase in extracellular LPS signaling receptor CD14, the consumption of fish-oils produced a protective intracellular response as observed by an increase in BAMBI and decrease in TGF-β1. These results suggest that a diet high in -3 fatty acids may protect against the development of hepatic fibrosis.